Imperagen Raises £5M Seed for AI-Driven Enzyme Engineering Platform
The AMW Read
Novelty 2: Imperagen introduces a recursive closed-loop lab pattern that updates the AI-biology segment baseline. Significance 2: The platform could reshape enzyme engineering timelines across pharma and industrial biotech, a segment-level impact.
Imperagen Raises £5M Seed for AI-Driven Enzyme Engineering Platform
Manchester-based techbio startup Imperagen has closed a £5 million seed round led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstone. Founded in 2021 by researchers from the Manchester Institute of Biotechnology, the company has developed a closed-loop platform that combines quantum physics simulations, problem-specific AI models, and automated robotics to dramatically accelerate enzyme engineering for pharmaceuticals, sustainable chemicals, and industrial biotech. The company reports improving the productivity of two enzymes by 677x and 572x in just five iterative rounds.
Why it matters: Imperagen exemplifies the emerging closed-loop lab pattern where AI models are continuously retrained on real-world experimental data rather than relying on static zero-shot predictions. This approach directly addresses a persistent failure of earlier computational biology tools — the gap between in silico predictions and real-world performance. By embedding the AI model inside a physical lab automation loop, the platform creates a self-improving system that grows more accurate with each experimental cycle. This is an early but structurally significant example of how AI-native biotech startups are redefining the traditional R&D pipeline, moving from isolated computational tools to integrated learning systems that treat the wet lab as a first-class data source.
The round also signals continued UK strength in AI-enabled biology, with Manchester emerging as a credible cluster outside the Cambridge-Oxford-London axis. The appointment of Guy Levy-Yurista, a CEO with deep tech exit experience, suggests the company is positioning for rapid commercial scaling. For enterprise biotech buyers, Imperagen's approach promises to compress enzyme development timelines from years to months, which could reshape production economics in high-value segments like pharmaceutical synthesis and sustainable chemistry.
#AIBiology #EnzymeEngineering #ClosedLoopAI #ManchesterDeepTech #IndustrialBiotech #SeedFunding
